A Phase 2 interventional study of Eltrombopag and Placebo in Myelodysplastic Syndromes, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 20 sites in Japan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing eltrombopag in Myelodysplastic Syndromes — none open to participants now, 2 under way, none of them phase 3. eltrombopag · Myelodysplastic Syndromes.
Among the 13 studies testing eltrombopag in Myelodysplastic Syndromes, this one is the 6th largest by enrollment, is the only one that started in 2021, is one of 8 in phase 2, and was the 12th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 13 studies testing eltrombopag in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 20 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 30 across the 13 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
37 studies in Myelodysplastic Syndromes by Novartis: none open now, 4 under way, none of them phase 3. Of 32 finished, 21 (66%) have results posted.
Among the 37 studies in Myelodysplastic Syndromes by Novartis, this one is the 23rd largest by enrollment, is one of 3 that started in 2021, is one of 15 in phase 2, and was the 32nd registered.
Novartis’s Myelodysplastic Syndromes studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing eltrombopag in Myelodysplastic Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 37 in Myelodysplastic Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk Myelodysplastic syndromes (LR-MDS).
This is a randomized, double-blind, placebo-controlled, Japanese local phase II study to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk MDS (IPSS-R very low, low, intermediate risk with bone marrow blast count \< 5% and cytogenetic very good, good or intermediate risk). Platelet transfusion dependence at baseline is defined as receiving platelet transfusion regularly with a frequency of 2 or more times within 4 weeks prior to randomization. Platelet transfusion should be performed for a patient with platelet counts \< 20 X 10\^9/L, or with hemorrhagic symptoms and platelet counts \< 30 X 10\^9/L.
The primary objective is to demonstrate superiority of eltrombopag versus placebo in terms of the proportion of participants who achieve platelet transfusion independence at Week 24.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prognostic Scoring System (IPSS-R):
Cytogenetic very good, good or intermediate risk corresponding to IPSS-R
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to a 1: 1 ratio will take eltrombopag.
Drug: Eltrombopag
Participants randomized to a 1: 1 ratio will take Placebo.
Drug: Placebo
Eltrombopag comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
Also known as: ETB115
Placebo comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
Percentage of participants who achieve platelet transfusion independence at Week 24
Platelet transfusion independence is defined as the absence of platelet transfusion for at least 8 weeks. Platelet count should be higher than the baseline count.
Time frame: Week 24
Time to platelet transfusion independence
This is defined as time from the date of randomization to the first day of a platelet transfusion-free period lasting at least 8 weeks.
Time frame: Year 1, Year 2
Duration of platelet transfusion independence
This is defined for participants who have achieved platelet transfusion independence only and will be calculated from the first date of platelet transfusion-free resulting in achievement of transfusion independence to the date before becoming platelet transfusion dependent.
Time frame: Year 1, Year 2
Percentage of participants with platelet transfusion independence
Platelet transfusion independence is defined as the absence of platelet transfusion for at least 8 weeks. Platelet count should be higher than the baseline count.
Time frame: Year 1, Year 2
Percentage of participants with platelet transfusion frequency reduction at Week 24
This is defined as a reduction by at least 50 percent during the 4 prior weeks as compared to the 4 weeks prior to randomization.
Time frame: Week 24
Percentage of participants with platelet response (Hematologic improvement (HI) - platelet))
Platelet response is defined as HI-platelet per International Working Group criteria.
Time frame: Week 24, Year 1, Year 2
Time to platelet response
This is defined as time from the date of randomization to the first date of achieving the platelet response criteria per modified IWG criteria.
Time frame: Week 24, Year 1, Year 2
Duration of platelet response
This is defined for participants who have achieved platelet response and will be calculated from the first date of achieving the platelet response criteria to the date before loss of platelet response per modified IWG criteria.
Time frame: Week 24, Year 1, Year 2
Percentage of hematologic improvement-erythroid and -neutrophil
per modified IWG criteria at 24 weeks, Year 1 and 2
Time frame: Week 24, Year 1, Year 2
Percentage of participants with disease progression excluding relapse after HI
This is with regards to blast counts for both investigator assessment and central review per modified IWG criteria.
Time frame: Week 24, Year 1, Year 2
Percentage of participants with relapse after HI and transfusion independence
The percentage of participants with relapse after HI and transfusion independence at Week 24, Year 1 and 2.
Time frame: Week 24, Year 1, Year 2
Percentage of participants with progression to Acute myeloid leukemia (AML)
This is defined as ≥ 20% blasts at Week 24, Year 1 and 2 for both investigator assessment and central review per WHO classification revised 4th edition.
Time frame: Week 24, Year 1, Year 2
Leukemia free survival (LFS)
This is defined as time from the date of randomization to progression to AML per WHO classification revised 4th edition of ≥ 20 percent blasts or death due to any cause for both investigator assessment and central review.
Time frame: Week 24, Year 1, Year 2
Clinically significant bleeding events
This is defined as ≥ grade 2 events as per WHO bleeding scale.
Time frame: Week 24, Year 1, Year 2
Overall survival (OS)
OS is defined as time from randomization to death due to any cause.
Time frame: Week 24, Year 1, Year 2
Quality of Life measured using QLQ-C30
The changes from baseline to each visit where measured using QLQ-C30. EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Subject's responses to 28 questions about their physical functioning, disease symptoms, global health status and utilities are scored on a 4-point scale (1=Not at all to 4=Very much), a low score indicates a high / healthy level of functioning. And the responses to 2 questions about health-related QoL are scored on a 7-point scale (1=Very poor to 7=Excellent), a high score indicates a high / healthy level of functioning. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.
Time frame: Baseline, every 4 weeks until week 52, every 8 weeks after week 52 up to end of treatment or end of post-treatment follow-up, approximately 3.5 years.
Pharmacokinetics (PK): Cmax
Full PK profile of eltrombopag over 24 hours at steady state at the initial dose, and at 125 mg and 150 mg when applicable, in subset of participants.
Time frame: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
PK: Tmax
Full PK profile of eltrombopag over 24 hours at steady state at the initial dose, and at 125 mg and 150 mg when applicable, in subset of participants.
Time frame: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
PK: AUC
Full PK profile of eltrombopag over 24 hours at steady state at the initial dose, and at 125 mg and 150 mg when applicable, in subset of participants.
Time frame: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
Trough concentrations of eltrombopag at steady state
at each dose level in all the participants
Time frame: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from May 2021 to primary completion in Apr 2025, 47 months.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 47 months is above that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag